Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Soliqua

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

- PMLiVE

Dendreon’s cancer vaccine wins EU approval

Provenge approved for use in prostate cancer three years after US recommendation

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

- PMLiVE

Sanofi pulls Lyxumia’s US filing

Says will resubmit diabetes drug for FDA approval in 2015

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links